



Attorney Docket No. VPI/02-142 US

DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION No.: 10/750,326  
CONFIRMATION No.: 4684  
FILING DATE: DECEMBER 31, 2003  
EXAMINER: NOT YET ASSIGNED  
GROUP ART UNIT: 1714  
APPLICANTS: SAUNDERS, ET AL.  
FOR: INHIBITORS OF PHOSPHATASES

August 26, 2005  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copy(ies) of references Citation No(s). **B1-B4; C1-C2** are attached.
- ☐ Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.).
- ☒ A copy of the International Search Report received in the corresponding PCT Application No. **PCT/US03/41661** is attached herewith.
- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

APPLICANTS: SAUNDERS, ET AL.  
APPLICATION NO.: 10/750,326

- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ In accordance with 37 C.F.R. § 1.98(a) (3) (i), references B1-B4; C1-C2 are relevant because they were cited in the International Search Report of the corresponding PCT application number PCT/US03/41661.

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED

APPLICANTS: SAUNDERS, ET AL.  
APPLICATION NO.: 10/750,326

Respectfully submitted,




Michael Badia, Reg. No. 51,424

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6619  
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class Mail in an envelope  
addressed to Commissioner for Patents, Mail Stop: Amendment,  
P.O. Box 1450, Alexandria, VA 22313-1450 on 8/26/05



Date of Signature

8/26/05




**Certificate Of Mailing Under 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On August 26, 2005  
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (B1-B4, C1-C2); and
4. Return Postcard Receipt.

  
\_\_\_\_\_  
Signature

Lisa M. Romano  
Typed or printed name of person signing Certificate



Modified Form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application Number	10/750,326
Filing Date	December 31, 2003
First Named Inventor	Jeffrey O. Saunders
Group Art Unit	1714
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/02-142 US

## U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 95/15963	BASF Aktiengesellschaft	15 June 1995	
	B2	WO 98/18781	Versicor, Inc.	7 May 1998	
	B3	WO 98/56770	BASF Aktiengesellschaft	17 December 1998	
	B4	EP 0 456 835	Kyorin Pharmaceutical Co., Ltd.	21 November 1991	

## OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Malamas, et al., "Quinazolineacetic Acids and Related Analogues as Aldose Reductase Inhibitors", J. Med. Chem., Vol. 34, No. 4, pp. 1492-1503 (1991).
	C2	Gordeev, et al., "A General and Efficient Solid Phase Synthesis of Quinazoline-2,4-diones.", Tetrahedron Letters, Vo. 38, No. 10, pp. 1729 -1732 (1997).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.